Twin Lakes Capital Management LLC Lowers Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Twin Lakes Capital Management LLC decreased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 11.8% during the 4th quarter, Holdings Channel reports. The fund owned 1,915 shares of the specialty pharmaceutical company’s stock after selling 256 shares during the quarter. Twin Lakes Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $236,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in JAZZ. Focus Partners Wealth acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $551,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $464,000. BTC Capital Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 9.4% in the fourth quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company’s stock valued at $6,115,000 after purchasing an additional 4,271 shares during the period. Summit Trail Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $539,000. Finally, Atria Investments Inc lifted its stake in shares of Jazz Pharmaceuticals by 19.5% in the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company’s stock valued at $336,000 after purchasing an additional 445 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity

In other news, Director Seamus Mulligan acquired 100,000 shares of the business’s stock in a transaction dated Friday, May 9th. The stock was acquired at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares in the company, valued at approximately $9,826,000. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the transaction, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at $4,826,778.66. This trade represents a 10.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,236 shares of company stock valued at $3,956,190 over the last 90 days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $108.07 on Friday. The firm has a 50 day simple moving average of $112.87 and a 200-day simple moving average of $121.88. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market cap of $6.66 billion, a PE ratio of 15.22, a P/E/G ratio of 1.04 and a beta of 0.38. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The business’s quarterly revenue was down .5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.68 EPS. On average, equities analysts expect that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price target for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $182.79.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.